

The Ferrous-dioxy Complex of Neuronal Nitric Oxide Synthase

DIVERGENT EFFECTS OF L-ARGININE AND TETRAHYDROBIOPTERIN ON ITS STABILITY*

(Received for publication, March 14, 1997, and in revised form, May 2, 1997)

Husam M. Abu-Soud‡§, Ratan Gachhui‡, Frank M. Raushel¶, and Dennis J. Stuehr‡§||

From the ‡Department of Immunology, The Cleveland Clinic Research Institute, Cleveland, Ohio 44195 and ¶Department of Chemistry, Texas A&M University, College Station, Texas 77843

Nitric oxide synthases (NOS) are hemeproteins that catalyze oxidation of L-arginine to nitric oxide (NO) and citrulline. The NOS heme iron is expected to participate in oxygen activation during catalysis, but its interactions with O₂ are not characterized. We utilized the heme-containing oxygenase domain of neuronal NOS (nNOSoxy) and stopped-flow methods to study formation and autooxidative decomposition of the nNOSoxy oxygenated complex at 10 °C. Mixing ferrous nNOSoxy with air-saturated buffer generated a transient species with absorption maxima at 427 and ~560 nm. This species decayed within 1 s to form ferric nNOSoxy. Its formation was first order with respect to O₂, monophasic, and gave rate constants for $k_{on} = 9 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ and $k_{off} = 108 \text{ s}^{-1}$ for an L-arginine- and tetrahydrobiopterin (H₄B)-saturated nNOSoxy. Omission of L-arginine and/or H₄B did not greatly effect O₂ binding and dissociation rates. Decomposition of the oxygenated intermediate was independent of O₂ concentration and was either biphasic or monophasic depending on sample conditions. L-Arginine stabilized the oxygenated intermediate (decay rate = 0.14 s⁻¹), while H₄B accelerated its decay by a factor of 70 irrespective of L-arginine. The spectral and kinetic properties of the intermediate identify it as the Fe^{II}O₂ complex of nNOSoxy. Destabilization of a metallo-oxy species by H₄B is unprecedented and may be important regarding the role of this cofactor in NO synthesis.

Nitric oxide (NO)¹ is an ubiquitous signal molecule involved in the regulation of several activities in the cardiovascular, nervous, and immune systems (1–4). NO is generated by a family of enzymes termed NO synthases (NOSs), which catalyze an NADPH- and O₂-dependent two-step oxidation of L-arginine to form NO and citrulline (5, 6). All NOSs are comprised of a C-terminal reductase domain that contains the binding sites for calmodulin (CaM), FMN, FAD, and NADPH and an N-terminal oxygenase domain that contains binding

sites for iron protoporphyrin IX (heme), tetrahydrobiopterin (H₄B), and substrate (L-arginine) (7–13). A variety of evidence suggests the individual oxygenase and reductase domains can fold and function independently (8–10, 13, 14). The neuronal NOS isoform (nNOS) is constitutively expressed in an inactive form that requires Ca²⁺-dependent CaM binding to activate its NO synthesis (15, 16). CaM activates NO synthesis in part by triggering an interdomain electron transfer between the flavin and heme centers of nNOS (17, 18).

The NOS heme iron is axially coordinated to the protein via a cysteine thiolate, as is the case for cytochrome P450s, and is predominantly five-coordinate and high spin in its ferric state (19–21). Substrate appears to bind directly above the heme and can interact with ligands bound to the heme iron, such as CO or NO (22, 23). During catalysis of NO synthesis, such positioning may alter heme iron reactivity or sterically specify substrate hydroxylation events as catalyzed by the heme iron. The H₄B cofactor is critical for stabilizing NOS dimeric structure and maintaining catalytic activity (24–26), and also affects the heme iron spin state, axial ligand stability, and binding of exogenous ligands (9, 27–29).

Reduction of the NOS heme iron is associated with activation of NO synthesis from L-arginine or with production of superoxide and H₂O₂ in the absence of substrate (17, 27, 30, 31). Heme iron reduction is thought to be critical for both activities because it may enable the enzyme to bind and activate O₂ (5, 6). Indeed, NO synthesis from either L-arginine or the reaction intermediate N^ω-hydroxyarginine is diminished in the presence of ligands that may prevent O₂ binding to the heme iron, such as CO or imidazole (32, 33). Although complexes between the NOS heme iron and CO, NO, and CN⁻ have been characterized spectroscopically (19–23, 34), direct evidence of O₂ binding to the NOS ferrous heme iron is not available.

To investigate what role the NOS heme plays in oxygen activation during catalysis, we utilized the oxygenase domain of nNOS² (nNOSoxy, amino acids 1–720) to study reactions between its ferrous heme iron and O₂. This report provides direct evidence for formation of a transient NOS Fe^{II}O₂ complex, and characterizes how bound L-arginine and H₄B effect its formation and decay kinetics.

EXPERIMENTAL PROCEDURES

Materials—Oxygen gas was purchased from Liquid Carbonic Company. All other reagents and materials were obtained from Sigma or from sources reported previously (14, 24, 30).

Protein Expression and Purification—Rat nNOS cDNA was a gift from Drs. David Bredt and Solomon Snyder at the John Hopkins University. The pCWori plasmid was used to overexpress the nNOSoxy (amino acids 1–723 with a six-histidine tag incorporated at the C terminus) in *Escherichia coli* strain BL21(DE3). The procedure to incorporate nNOSoxy cDNA into the pCWori plasmid was similar to that

* This study was supported by National Institute of Health Grant GM51491 (to D. J. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Immunology NN-1, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-6950; Fax: 216-444-9329.

|| Established Investigator of the American Heart Association.

¹ The abbreviations used are: NO, nitric oxide; nNOS, neuronal nitric oxide synthase; nNOSoxy, the oxygenase domain of nNOS; CaM, calmodulin; H₄B, (6R,6S)-2-amino-4-hydroxy-6-(L-erythro-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridine; PCR, polymerase chain reaction; PMSF, phenylmethylsulfonyl fluoride; EPPS, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid; Bis-Tris, 2-[bis(2-hydroxyethyl)-amino]-2-(hydroxymethyl)-propane-1,3-diol.

² Use of nNOSoxy eliminates spectral interference from bound flavin groups present in the full-length enzyme.




FIG. 2. Stopped-flow traces for the reaction of ferrous nNOSoxy with air-saturated buffer. The reaction was monitored at 410 nm (upper panel) and 440 nm (lower panel) in the presence of saturating L-arginine and H₄B. Points that are associated with maximum absorbance of individual nNOSoxy species are indicated in each panel.

lowed by a slower increase in absorbance. When the reaction was monitored at 440 nm (lower panel), the direction of absorbance change was reversed but otherwise proceeded with identical kinetics. At either wavelength, the absorbance observed at the start of the reaction can be attributed to ferrous nNOSoxy, while the absorbance at the inflection and end points can be attributed to sequential formation of the transient intermediate and ferric nNOSoxy, respectively. We thus monitored the reaction at a range of single wavelengths and plotted the maximum absorbance obtained for each of the three species as a function of wavelength. As shown in Fig. 3, the spectra so derived match the rapid scanning spectra reported in Fig. 1 and are consistent with the sequential nature of the proposed reaction. Fitting each stopped-flow trace obtained at single wavelengths to a two-exponential function showed that there was no variation in the observed rate constants for formation or autooxidation. This indicates that the transient intermediate and ferric nNOSoxy are the only two observable products of the reaction.

We next examined the formation and decay of the transient species as a function of O₂ concentration by monitoring absorbance change at 410 nm. The pseudo-first order rate constants obtained for its formation in the presence of saturating L-arginine and H₄B are plotted as a function of O₂ concentration in panel A of Fig. 4. The association and dissociation rate constants derived from the graph are listed in Table I along with rate constants obtained under similar conditions for nNOSoxy samples saturated either with L-arginine or H₄B alone or in the absence of both molecules.

As shown in panel B of Fig. 4, the decay rate of the transient species did not change with O₂ concentration, indicating decay is independent of dissolved O₂. The autooxidation rate for the




FIG. 3. Spectra of the ferric, ferrous, and oxygenated nNOSoxy species derived from single wavelength stopped-flow analysis. Ferrous nNOSoxy was rapid-mixed with air-saturated buffer in the presence of saturating L-arginine and H₄B. Stopped-flow traces were obtained at the single wavelengths indicated by the position of each symbol. The maximum absorbance due to each of the three nNOS species was obtained from the kinetic traces at each wavelength (as exemplified in Fig. 2) and used to construct a spectrum for each species.




FIG. 4. Effect of O₂ concentration on the formation and decay of the oxygenated nNOSoxy complex. A solution of 2 μM ferrous nNOSoxy containing 1 mM L-arginine and 10 μM H₄B was rapid-mixed at 10 °C with buffer containing different O₂ concentrations. Panel A plots the observed rates of complex formation at 410 nm versus O₂ concentration, while panel B plots the observed decay rates of the oxygenated nNOSoxy complex at 410 nm versus O₂ concentration.

H₄B- and L-arginine-saturated protein was best fit to a single exponential function and was therefore monophasic, giving a rate of 10 s⁻¹ (Table I). An identical monophasic decay rate was also observed with nNOSoxy that was saturated with H₄B alone (Table I). However, decay of the transient species in nNOSoxy samples devoid of both L-arginine and H₄B was biphasic, giving rate constants of 2.3 s⁻¹ and 0.12 s⁻¹ (Table I). Again, these decay rates did not change as a function of O₂ concentration (data not shown). With an nNOS sample satu-

TABLE I
Rate constants for formation and decay of the oxygenated nNOSoxy complex

Ferrous nNOSoxy in the presence or absence of L-arginine and/or H₄B was rapid-mixed with buffer containing O₂ at various concentrations. Rates of complex formation and decay were determined by following absorbance change at 410 nm, and the rate constants determined as described in the text.

Conditions	k_{on} $M^{-1}s^{-1}$	k_{off}	Decay s^{-1}
-L-Arginine - H ₄ B	1.4×10^6	177	0.12, 2.3
+L-Arginine - H ₄ B	1.1×10^6	65	0.14
-L-Arginine + H ₄ B	7.8×10^5	130	10
+L-Arginine + H ₄ B	9.0×10^5	108	10


rated with L-arginine alone, only the slow decay rate was observed (Table I).

DISCUSSION

These data provide the first direct evidence for O₂ binding to the NOS heme iron, consistent with its proposed role in oxygen activation during NO synthesis (5, 6). Mixing an O₂-containing solution with ferrous nNOSoxy resulted in rapid formation of a transient intermediate whose spectral and kinetic characteristics were quite similar to the Fe^{II}O₂ complexes of a number of cytochrome P-450s (36–44), identifying the intermediate as Fe^{II}O₂ nNOSoxy. Although its Soret maxima (427 nm) is somewhat red-shifted compared with most Fe^{II}O₂ cytochrome P-450s which absorb maximally at 418–420 nm (36–40, 42–44), it is most similar to the Fe^{II}O₂ complex of substrate-bound cytochrome P-450_{SCC} which absorbs maximally at 423 nm (41). The spectral features of Fe^{II}O₂ nNOSoxy did not change noticeably in the absence of bound substrate (L-arginine) or H₄B (data not shown), consistent with bound substrate also not altering the visible spectra of the ferrous-CO or -NO complexes of nNOS (19, 23, 30).

In air-saturated solution, formation of the nNOSoxy Fe^{II}O₂ complex occurred at rates that were 40–4000 times faster than complex decay. Under such circumstances, practically all of the nNOSoxy sample exists in its Fe^{II}O₂ form prior to decay.³ Rates of complex formation and decay were invariant as a function of wavelength and both processes generated spectral isosbestic points. This indicates that complex formation and decay occur without formation of other observable intermediates, which is also the case for most cytochrome P450s examined to date (36, 40). Formation of Fe^{II}O₂ nNOSoxy was first order with respect to O₂, reversible, and followed a simple one-step mechanism. Decay of the complex was independent of O₂ concentration, occurred via a one- or two-exponential process depending on sample conditions, and generated ferric nNOSoxy as a product. A model consistent with the data is shown in Scheme 1. Mechanisms proposed for the autooxidation of Fe^{II}O₂ hemeproteins generally involve electron transfer to O₂ as a primary step to form superoxide, which undergoes further irreversible reactions (45, 46). Indeed, uncoupled NADPH oxidation by nNOS is reported to generate superoxide as a primary product (31). However, because cytochrome P-450s can also generate H₂O₂ or water as primary products of uncoupled oxidation (36, 47, 48), it is possible that nNOS may form these products under favorable conditions.

³ This enabled us to estimate an extinction coefficient for the nNOSoxy Fe^{II}O₂ complex ($64.1 \text{ mM}^{-1} \text{ cm}^{-1}$ at 427 nm), which is lower than the estimated extinction coefficients of ferric or ferrous nNOSoxy (76 and $69.1 \text{ mM}^{-1} \text{ cm}^{-1}$ at 400 and 414 nm, respectively).




SCHEME 1

Dioxygen binding to ferrous nNOSoxy was fast enough to be kinetically competent regarding NO synthesis (5, 6), and the second order rate constants were comparable to that published for ferrous cytochrome P-450_{CAM} (40). However, estimated rate constants for O₂ dissociation from ferrous nNOSoxy were one to two orders of magnitude greater than that published for P-450_{CAM} (40). The reason for this difference is unclear. L-arginine or H₄B did not significantly influence O₂ binding and dissociation rates, suggesting that the O₂ interaction is not greatly influenced by bound substrate or pterin. This differs from CO, whose rebinding to the nNOS heme is decreased 12-fold in the presence of bound L-arginine (34). We speculate this difference may arise from steric constraints in the distal pocket brought on by substrate and pterin that appear to force a bent Fe^{II}-ligand geometry (22, 23) instead of the linear geometry particularly favored by ferrous-CO complexes.

In the absence of L-arginine and H₄B, the autooxidation of Fe^{II}O₂ nNOSoxy was biphasic, giving rate constants of 0.12 and 2.3 s⁻¹. Only the slow decay rate was observed in the presence of L-arginine, implying that bound substrate stabilizes Fe^{II}O₂ nNOSoxy. Biphasic decay in the absence of substrate and/or stabilization in its presence have also been reported for some Fe^{II}O₂ cytochrome P-450s (36, 41, 44). However, even in its most stable form (*i.e.* L-arginine-bound) the Fe^{II}O₂ nNOSoxy complex still decays 2 or 100 times faster than the substrate-bound Fe^{II}O₂ complexes of cytochrome P-450_{SCC} (41) and P-450_{CAM} (40), respectively.

Remarkably, bound H₄B accelerated the decay of Fe^{II}O₂ nNOS by a factor of 70 even in the presence of bound L-arginine. The apparent ability of H₄B to destabilize an oxy-iron complex is unprecedented and represents a new role for pterins in biology. The impact of this finding on NOS catalysis is not yet clear. However, it is pertinent to discuss with regard to oxygen activation during NO synthesis, which is thought to proceed as in the cytochrome P-450s (reviewed in Ref. 49) (Scheme 2).



SCHEME 2

Initial reduction of the ferric heme iron enables formation of the Fe^{II}O₂ species (I). Transfer of a second electron is thought to generate an iron-peroxy intermediate (II) that loses water and forms a high valence oxo-iron species (III) that can carry out substrate hydroxylation.

In NOS, the Fe^{II}O₂ species (I) has been proposed to play a different role in each step of catalysis (5, 6). In the first step (*N*-hydroxylation of L-arginine) it may function solely as an intermediate on the path to the oxo-iron species (III) that is thought to hydroxylate L-arginine. However, in the second step (conversion of the *N*-hydroxyarginine intermediate to NO and citrulline) the Fe^{II}O₂ species (I) may instead act as an oxidant that removes an electron or hydrogen atom from bound *N*-hydroxyarginine.⁴ Thus, productive oxygen activation in both

⁴ An investigation of nNOS catalysis under single turnover conditions shows that the Fe^{II}O₂ species can catalyze the second step of NO synthesis, consistent with its acting as an oxidant in this step (H. M. Abu-Soud, P. A. Presta, B. Mayer, and D. J. Stuehr, unpublished results).

steps of NO synthesis may require that a second electron be provided to the Fe^{II}O₂ complex. When viewed this way, destabilization of the Fe^{II}O₂ complex by H₄B seems counterproductive, because it would favor a decomposition reaction that yields ferric nNOS and superoxide instead of further reductive steps that lead to NO synthesis. However, the fact that NO synthesis by nNOS is tightly coupled to NADPH oxidation in the presence of saturating H₄B (5, 6) suggests that decay of the Fe^{II}O₂ species under normal reaction conditions is slower than the additional reductive steps required to activate oxygen for productive catalysis.

Recent work with H₄B-free forms of nNOS (27) and inducible NOS⁵ shows that they can catalyze NADPH-dependent, heme iron-based O₂ consumption in the presence of bound L-arginine without catalyzing NO synthesis. This implies that formation of oxygenated iron species within the active site can occur in the absence of H₄B but is itself not sufficient to support NO synthesis. Thus, we speculate that H₄B destabilization of the nNOSoxy Fe^{II}O₂ complex as described here may actually reflect a more global influence of H₄B on the reactivity of all nNOS iron-oxy species that somehow enables oxygen activation at the heme to become coupled to NO synthesis. Our current findings provide a foundation to explore this hypothesis.

Acknowledgments—We thank Pam Clark, Jingli Zhang, Bryant Miles, and Suk-Bong Hong for excellent technical assistance.

REFERENCES

- Ignarro, L. J. (1990) *Annu. Rev. Pharmacol. Toxicol.* **30**, 535–560
- Moncada, S., Palmer, R. M. J., and Higgs, E. A. (1991) *Pharmacol. Rev.* **43**, 109–142
- Schmidt, H. H. H. W., and Walter, U. (1994) *Cell* **78**, 919–925
- Vincent, S. R. (1994) *Prog. Neurobiol.* **42**, 129–160
- Marletta, M. A. (1993) *J. Biol. Chem.* **268**, 12231–12234
- Griffith, O. W., and Stuehr, D. J. (1995) *Annu. Rev. Physiol.* **57**, 707–736
- Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Snyder, S. H. (1991) *Nature* **351**, 714–718
- Sheta, E. A., McMillan, K., and Masters, B. S. S. (1994) *J. Biol. Chem.* **269**, 15147–15153
- McMillan, K., and Masters, B. S. S. (1995) *Biochemistry* **34**, 3686–3693
- Ghosh, D. K., Abu-Soud, H. M., and Stuehr, D. J. (1996) *Biochemistry* **35**, 1444–1449
- Klatt, P., Schmidt, K., Brunner, F., and Mayer, B. (1994) *J. Biol. Chem.* **269**, 1674–1680
- Ghosh, D. K., and Stuehr, D. J. (1995) *Biochemistry* **34**, 801–807
- Chen, P.-F., Tsai, A.-L., Berka, V., and Wu, K. K. (1996) *J. Biol. Chem.* **271**, 14631–14635
- Gachhui, R., Presta, A., Bentley, D. F., Abu-Soud, H. M., McArthur, R., Brudvig, G., Ghosh, D. K., and Stuehr, D. J. (1996) *J. Biol. Chem.* **271**, 20594–20602
- Nakane, M., Schmidt, H. H. H. W., Pollock, J. S., Forstermann, U., and Murad, F. (1993) *FEBS Lett.* **316**, 175–180
- Su, Z., Blazing, M. A., Fan, D., and George, S. E. (1995) *J. Biol. Chem.* **270**, 29117–29122
- Abu-Soud, H. M., and Stuehr, D. J. (1993) *Proc. Natl. Acad. Sci. U. S. A.* **90**, 10769–10772
- Abu-Soud, H. M., Yoho, L. L., and Stuehr, D. J. (1994) *J. Biol. Chem.* **269**, 32047–32050
- McMillan, K., Bredt, D. S., Hirsch, D. J., Snyder, S. H., Clark, J. E., and Masters, B. S. S. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 11141–11145
- Sono, M., Stuehr, D. J., Ikeda-Saito, M., and Dawson, J. H. (1995) *J. Biol. Chem.* **270**, 19943–19948
- Stuehr, D. J., and Ikeda-Saito, M. (1992) *J. Biol. Chem.* **267**, 20547–20550
- Wang, J., Stuehr, D. J., Ikeda-Saito, M., and Rousseau, D. L. (1993) *J. Biol. Chem.* **268**, 22255–22258
- Wang, J., Rousseau, D. L., Abu-Soud, H. M., and Stuehr, D. J. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 10512–10516
- Baek, K. J., Thiel, B. A., Lucas, S., and Stuehr, D. J. (1993) *J. Biol. Chem.* **268**, 21120–21129
- Klatt, P., Schmidt, K., Lehner, D., Glatter, O., Bachinger, H. P., and Mayer, B. (1995) *EMBO J.* **14**, 3687–3695
- Hevel, J. M., and Marletta, M. A. (1992) *Biochemistry* **31**, 7160–7165
- Gorren, A. C. F., List, B. M., Schrammel, A., Pitters, E., Hemmens, B., Werner, E. R., Schmidt, K., and Mayer, B. (1996) *Biochemistry* **35**, 16735–16745
- Wang, J., Stuehr, D. J., and Rousseau, D. L. (1995) *Biochemistry* **34**, 7080–7087
- Rodriguez-Crespo, I., Gerber, N. C., and Ortiz de Montellano, P. R. (1996) *J. Biol. Chem.* **271**, 11462–11467
- Abu-Soud, H. M., Feldman, P. L., Clark, P., and Stuehr, D. J. (1994) *J. Biol. Chem.* **269**, 32318–32326
- Pou, S., Pou, W. S., Bredt, D. S., Snyder, S. H., and Rosen, G. M. (1992) *J. Biol. Chem.* **267**, 24173–24176
- Pufahl, R. A., and Marletta, M. A. (1993) *Biochem. Biophys. Res. Commun.* **193**, 963–970
- Wolff, D. J., Datto, G. A., Samatovicz, R. A., and Tempsick, R. A. (1993) *J. Biol. Chem.* **268**, 9425–9429
- Matsuoka, A., Stuehr, D. J., Olson, J. S., Clark, P., and Ikeda-Saito, M. (1994) *J. Biol. Chem.* **269**, 20335–20339
- Abu-Soud, H. M., Loftus, M., and Stuehr, D. J. (1995) *Biochemistry* **34**, 11167–11175
- Opridan D. D., Gorsky L. D., and Coon M. J. (1983) *J. Biol. Chem.* **258**, 8684–8691
- Guengerich, F. P., Ballou, D. P., and Coon, M. J. (1976) *Biochem. Biophys. Res. Commun.* **70**, 951–956
- Tyson, C. A., Lipscomb, J. D., and Gunsalus, I. C. (1972) *J. Biol. Chem.* **247**, 5777–5784
- Ishimura, Y., Ullrich, V., and Peterson, J. A. (1971) *Biochem. Biophys. Res. Commun.* **42**, 140–146
- Peterson, J. A., Ishimura, Y., and Griffin, B. W. (1972) *Arch. Biochem. Biophys.* **149**, 197–208
- Tuckey, R. C., and Kamin, H. (1982) *J. Biol. Chem.* **257**, 9309–9314
- Larroque, C., and Van Lier, J. E. (1980) *FEBS Lett.* **115**, 175–177
- Eisenstein, L., Debey, P., and Douzou, P. (1977) *Biochem. Biophys. Res. Commun.* **77**, 1377–1283
- Bonfils, C., Debey, P., and Maurel, P. (1979) *Biochem. Biophys. Res. Commun.* **88**, 1301–1307
- Momenteau M., and Reed C. A. (1994) *Chem. Rev.* **94**, 659–698
- Sligar, S. G., Lipscomb, J. D., Debrunner, P. G., and Gunsalus, I. C. (1974) *Biochem. Biophys. Res. Commun.* **61**, 290–296
- Loida, P. J., and Sligar, S. G. (1993) *Biochemistry* **32**, 11530–11538
- Gorsky, L. D., Koop, D. R., and Coon, M. J. (1984) *J. Biol. Chem.* **259**, 6812–6817
- Guengerich, F. P., and Macdonald, T. L. (1990) *FASEB J.* **4**, 2453–2459

⁵ P. A. Presta, U. Siddhanta, and D. J. Stuehr, unpublished results.

ENZYMOLOGY:

**The Ferrous-dioxy Complex of Neuronal
Nitric Oxide Synthase: DIVERGENT
EFFECTS OF L-ARGININE AND
TETRAHYDROBIOPTERIN ON ITS
STABILITY**

Husam M. Abu-Soud, Ratan Gachhui, Frank
M. Raushel and Dennis J. Stuehr
J. Biol. Chem. 1997, 272:17349-17353.
doi: 10.1074/jbc.272.28.17349

Access the most updated version of this article at <http://www.jbc.org/content/272/28/17349>

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](#).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 49 references, 24 of which can be accessed free at
<http://www.jbc.org/content/272/28/17349.full.html#ref-list-1>